Pulmonx reports positive CONVERT trial results for AeriSeal emphysema system

Pulmonx announced publication of CONVERT Trial results for its AeriSeal System in severe emphysema patients. AeriSeal converted collateral ventilation status in 75.8% of evaluable patients, after which 88.9% achieved target-lobe volume reduction with Zephyr Valves at 45 days; the reduction continued through 12 months. Pulmonx is enrolling the CONVERT II Pivotal Trial to support a U.S. Premarket Approval application for AeriSeal.

AeriSeal remains under clinical evaluation, so U.S. commercialization depends on the ongoing CONVERT II study and its intended six-month results. The reported outcomes expand the potential group of emphysema patients who could qualify for subsequent Zephyr Valve treatment, while the company continues pursuing FDA approval.

  • 1The CONVERT Trial enrolled 101 patients across 14 sites in Europe and Australia.
  • 2AeriSeal converted collateral ventilation positive lobes to collateral ventilation negative status in 75.8% of evaluable patients.
  • 3At 45 days after Zephyr Valve placement, 88.9% of evaluable patients achieved target-lobe volume reduction, which persisted through 12 months.
  • 4CONVERT II is designed to enroll approximately 200 patients internationally and in the United States under an Investigational Device Exemption.
  • 5Six-month CONVERT II results are intended to support Pulmonx’s U.S. Premarket Approval application for AeriSeal.

Sources